No abstract

Objectives: To evaluate the value of PCR HPV test with Thinprep cytology test for detection of cervical human papillomavirus changes.Method: Seventy women were studied. All patients were subjected to speculum examination followed by thin-prep cytology test and Multiplex PCR HPV analysis. Results: ThinPrep cytology result test was NILM in 12 (17.1%) patients, 36 (51.4%) patients had ASC-US, 20 (28.6%) had (LSIL) and 2 (2.9 %) had HSIL. PCR HPV was negative in 26 (37.2%) patients, 24 (34.3%) patients had low risk HPV types, 10 (14.3) patients had HPV 16, 5 (7.1%) patients had HPV 18 infection. ThinPrep cytology result was significantly related to conventional PAP smear result (P =0.030) and PCR HPV result (P=0.000). ThinPrep test was more sensitive but less specific than PCR HPV test. Conclusion: The combined use of ThinPrep cytology test and PCR HPV test can play a significant role towards accurate diagnosis and screening of cervical cancer.

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease that displays a highly variable clinical outcome. It is a neoplasm of large transformed B cells with a diffuse growth pattern. DLBCL is the most common type of non-Hodgkin's lymphoma (NHL) (31% of all cases). Approximately half of patients with DLBCL are cured with current chemotherapy regimens. The purpose of this study was to evaluate BCl2 expression in 45 patients diagnosed with DLBCL of head and neck region and correlate the level of its immunohistochemical expression with different clinicopathological variables with emphasis upon patients' age, gender, nodal or extra-nodal location of lymphoma, patients' response to chemotherapy, progression-free survival (PFS) and overall survival (OS). A retrospective analysis of 45 patients diagnosed to have DLBCL. A cut off value of ≥ 50% protein expression denoted BCL2 positivity. Out of 45 cases, 36 cases (80%) revealed BCL2 positive expression and 9 cases (20%) were BCL2 negative. We found statistically significant differences in BCL2 expression regarding different patients' responses to chemotherapy, patients' OS and PFS (p ≤ 0.05). No statistically significant differences in BCL2 expression regarding the patients' Ann Arbor clinical stage, age group and tumor site (nodal or extra-nodal, p > 0.05) using the Chi-square test. BCL2 expression was analyzed in relation to 5 years OS and PFS using Kaplan Meier curves and Log Rank test for survival analysis. Cases that demonstrated BCL2 positivity revealed shortened OS and PFS with highly statistically significant differences among the studied variables (p = 0.000). We also found that patients who respond well to the chemotherapeutic regimen had negative BCL2 expression, the differences were statistically signifi-cant (p = 0.015). In conclusion, BCL2 expression could be considered a predictor for patients' chemotherapeutic response, OS and PFS.